The Janus face of immune stimulation by nanomedicines: Examples for the good and the bad

European Journal of Nanomedicine

Volumn 3, Issue 1, 2010, Pages 13-18

  Lisziewicz, Julianna ^a,b   Szebeni, Janos ^c  

^a Genetic Immunity   (Hungary)

^b Semmelweis University Budapest ^*  (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anaphylaxis; Dendritic cells; First line HIV therapy; Hypersensitivity reactions; Immune toxicity; Immunotherapy; Infusion reactions; Nanoparticles; Vaccine

Indexed keywords

ANAPHYLAXIS; DENDRITIC CELLS; FIRST-LINE HIV THERAPY; HYPERSENSITIVITY REACTIONS; IMMUNE TOXICITY; IMMUNOTHERAPY; INFUSION REACTIONS;

CELLS; NANOPARTICLES; TOXICITY; VACCINES; VIRUSES;

IMMUNOLOGY;

BETA1A INTERFERON; ERYPRO; ETANERCEPT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INFLIXIMAB; INSULIN GLARGINE; NANOPARTICLE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; LANGERHANS CELL; MEMORY T LYMPHOCYTE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; REVIEW;

EID: 79954556479     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.3884/0003.1.5     Document Type: Review

References (35)

1. Tocombining double acute accentke RE, Locombining double acute accentrincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int J Pharm. 2010;In Press:
2. Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res. 2009;11:1251-1310.
3. Plank C, Mechtler K, Szoka FC, Jr., Wagner E . Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery . Hum Gene Therapy. 1996;7:1437-1446 . (Pubitemid 26293564)
4. Toda M, Kitazawa T, Hirata I, Hirano Y, Iwata H. Complement activation on surfaces carrying amino groups. Biomaterials 2008;29:407-417 . (Pubitemid 350100797)
5. Peng Q, Li K, Wang N, Li Q, Asgar E, Lu B, Woodruff TM, Sacks SH, Zhou W. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol. 2009;183:6058-68.
6. Lisziewicz, J, Gabrilovich DI, Varga G, Xu J, Greenberg PD, Arya SK, Bosch M, Behr J-P, Lori F. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J Virol. 2001;75:7621-7628. (Pubitemid 32738020)
7. Cristillo AD, Lisziewicz J, He L, Lori F, Galmin L, Trocio JN, Unangst T, Whitman L, Hudacik L, Bakare N, Whitney S, Restrepo S, Suschak J, Ferrari MG, Chung HK, Kalyanaraman VS, Markham P, Pal R. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 2007;366:197-211. (Pubitemid 47314400)
8. Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine 2007;25:3070-4. (Pubitemid 46482736)
9. Lisziewicz J, Trocio J, Xu J, Whitman L, Ryder A, Bakare N, Lewis MG, Wagner W, Pistorio A, Arya S, Lori F. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005;19:35-43. (Pubitemid 40111016)
10. ClinicalTrials. Clicical trials gov IDs: NCT00711230, NCT00270205, NCT00918840.
11. Haxby JA, Kinsky CB, Kinsky SC. Immune response of a liposomal model membrane. Proc Natl Acad Sci US. 1968;61:300-307.
12. Haxby JA, Gotze O, Muller-Eberhard HJ, Kinsky SC. Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci USA 1969;64:290-295.
13. Alving CR, Kinsky SC, Haxby JA, Kinsky CB. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969;8:1582-1587.
14. Kinsky SC, Haxby JA, Zopf DA, Alving CR, Kinsky CB. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969;8:4149-58.
15. Alving CR. Antibodies to lipids and liposomes: immunology and safety. J Liposome Res. 2006;16:157-66. (Pubitemid 44358989)
16. Erdei A, Molnár E, Csomor E, Bajtay Z, Prechl J. (2004). Coordination of Adaptive Immune Responses by C3. In The Complement System: Novel Roles in Health and Disease (Szebeni, J., ed.), pp. 77-96. Kluwer, Boston.
17. Morgan EL. Modulation of the immune response by anaphylatoxins. Complement 1986;3:128-136. (Pubitemid 17208217)
18. Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van Der Meer JW, Corstens FH, Boerman OC. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292:1071-9. (Pubitemid 30136603)
19. Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E, Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm. 2008;362:197-200.
20. Erdei A, Köhler V, Schéfer H, Burger R. Macrophage-bound C3 fragments as adhesion molecules modulate presentation of exogenous antigens. Immunobiology 1992;185:314-326.
21. Roberts ML, Luxembourg AT, Cooper NR. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. J Gen Virol. 1996;77:3077-3085.
22. Roberts T, Snow EC. Cutting edge: recruitment of the CD19/CD21 coreceptor to B cell antigen receptor is required for antigen-mediated expression of Bcl-2 by resting and cycling hen egg lysozyme transgenic B cells. J Immunol. 1999;162:4377-4380. (Pubitemid 29314831)
23. Carroll MC. CD21/CD35 in B cell activation. Semin Immunol. 1998;10:279-286. (Pubitemid 28375303)
24. Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol. 1998;10:36-40. (Pubitemid 28112076)
25. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Annu Rev Immunol. 1998;16:545-568. (Pubitemid 28183376)
26. Carroll M. Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Curr Top Microbiol Immunol. 1999;246:63-69. (Pubitemid 29225960)
27. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, Stahl GL, Bünger R, Alving CR. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999;99:2302-2309.
28. Szebeni J, Baranyi B, Savay S, Bodo M, Morse DS, Basta M, Stahl GL, Bunger R, Alving CR. Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol. 2000;279:H1319-H1328.
29. Szebeni J. (2004). Complement activation-related pseudoallergy: Mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents . In The Complement System: Novel Roles in Health and Disease (Szebeni, J., ed.), pp. 399-440. Kluwer, Boston.
30. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005;216:106-121. (Pubitemid 41712000)
31. Szebeni J, Bunger R, Baranyi L, Bedocs P, Toth M, Rosivall L, Barenholz Y, Alving CR. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res. 2007;17:107-117. (Pubitemid 47026981)
32. Chanan-Khan A, Szebeni, J. Savay, S. Liebes, L. Rafique, N.M., Alving, C.R. Muggia FM. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003;14:1430-1437.
33. The Complement Factsbook. Factsbook Series (Bernard, J. & Morley, M. J., Eds.), Walport Paperback, 2000).
34. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol. 2008;46:225-32.
35. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.